康柏西普联合改良格栅激光治疗难治性DME的疗效观察

Curative effect of compathopril combined with modified grid laser in the treatment of refractory DME

目的探究康柏西普联合改良格栅激光治疗难治性糖尿病性黄斑水肿(DME)的疗效观察.方法选取本院90例难治性DME患者作为观察对象,随机将其分为3组,各30例.使用改良格栅激光联合曲安奈德玻璃体腔注射进行治疗的患者为A组,先进行改良格栅激光治疗后进行康柏西普注射的30例患者为B组,先进行康柏西普注射后进行改良格栅激光的30例患者为C组.对比3组的黄斑中心凹厚度及治疗后不良反应(眼部感染、眼部胀痛、眼压升高、白内障)发生率来评估治疗效果.结果经治疗后,3组的黄斑中心凹厚度均薄于治疗前(P<0.05),C组与B组的黄斑中心凹厚度比较差异无统计学意义,C组与B组的黄斑中心凹厚度均明显薄于A组(P<0.05);C组发生的不良反应的例数最少,并且C组的不良反应发生率显著低于A组(P<0.05).结论康柏西普联合改良格栅激光可显著降低难治性DME患者的黄斑中心凹厚度,并且先进行康柏西普注射,再进行改良格栅激光治疗可以减少不良反应风险,因此该法具备临床推广价值.

Objective To investigate the effect of compactopril combined with modified grid laser in the treatment of refractory diabetic macular edema (DME). Methods 90 patients with refractory DME in our hospital were randomly divided into 3 groups. 30 patients were treated with modified grid laser and triamcinolone acetonide intravitreal injection. Thirty patients treated with modified grid laser were divided into group B and group C. The thickness and results of macular fovea in the three groups were compared. Results After treatment, the thickness of fovea maculae in three groups was thinner than that before treatment (P<0.05). There was no significant difference between group C and group B. The thickness of fovea maculae in group C and group B was significantly thinner than that in group A (P<0.05). The number of adverse reactions in group C was the least, and the adverse reactions in group C were the least. The birth rate was significantly lower than that of group A (P<0.05). Conclusion Compactopril combined with modified grid laser can significantly reduce the thickness of macular fovea in patients with refractory DME, and it is possible to reduce the risk of adverse reactions by first injection of Compactopril and then by modified grid laser. Promotion value.